Evidence map›Paper›PMID 30603390›Full record

ArticleTissue engineering and regenerative medicine2016

Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy.

Jun-Won Yun, Jae-Bum Ahn, Euna Kwon, Jae Hun Ahn, Hyung Woo Park, Hwon Heo, Jin-Sung Park, Hyeonjin Kim, Sun Ha Paek, Byeong-Cheol Kang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tissue engineering and regenerative medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Extracellular Vesicles in Neurodegenerative Diseases: A Double-Edged Sword.Tissue engineering and regenerative medicine · 2017
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jun-Won Yun1Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Jae-Bum Ahn1Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Euna Kwon1Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Jae Hun Ahn1Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Hyung Woo Park3Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.
Hwon Heo4Department of Biomedical Sciences, Seoul National University, Seoul, Korea.
Jin-Sung Park5Department of Neurogenetics, Kolling Institute of Medical Research, Royal North Shore Hospital and the University of Sydney, St. Leonards, New South Wales, Australia.
Hyeonjin Kim4Department of Biomedical Sciences, Seoul National University, Seoul, Korea.
Sun Ha Paek3Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.
Byeong-Cheol Kang1Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Seoul National University · KRSeoul National University Hospital · KRRoyal North Shore Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell technologies are particularly attractive in Parkinson's disease (PD) research although they occasionally need long-term treatment for anti-parkinsonian activity. Unfortunately, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) widely used as a model for PD has several limitations, including the risk of dose-dependent mortality and the difficulty of maintenance of PD symptoms during the whole experiment period. Therefore, we tested if our novel MPTP regimen protocol (2 mg/kg for 2 consecutive days and 1 mg/kg for next 3 consecutive days) can be maintained stable parkinsonism without mortality for long-term stem cell therapy. For this, we used small-bodied common marmoset monkeys (

Indexed as

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimal modelMarmosetNonhuman primateParkinson’s disease

Identifiers

PMID30603390
PMCPMC6170997
OpenAlexW2200631037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.